Table 3. Clinical baseline information of all the included patients.
| Study | No. patients | Age | BMI | PSA | Prostate volume | Gleason score | Staging of tumor | ASA | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E/F | Non-E/F | E/F | Non-E/F | E/F | Non-E/F | E/F | Non-E/F | E/F | Non-E/F | E/F | Non-E/F | E/F | Non-E/F | E/F | Non-E/F | ||||||||
| Gralla et al., 2007 | 25 | 25 | 61.80±4.75 | 62.24±7.01 | 25.82±2.55 | 25.84±3.00 | 7.29±4.99 | 10.24±8.40 | 45.37±13.52 | 45.72±20.09 | 6.00±1.04 | 5.92±1.14 | T1, 100% | T1, 100% | 2, 100% | 2, 100% | |||||||
| Parrado et al., 2008 | 60 | 26 | The author stated no difference | NA | NA | 8.11±4.14 | 7.16±3.81 | 41.51±18.40 | 34.01±11.56 | 6.27±0.55 | 6.35±0.80 | NA | NA | NA | NA | ||||||||
| Ahmed et al., 2011 | 25 | 25 | 61.8±4.7 | 61.9±7.0 | NA | NA | 7.2±4.9 | 10.3±8.6 | NA | NA | ≤6, 76%; =7, 20%; ≥8, 4% |
≤6, 80%; =7, 12%; ≥8, 8% |
T1c, 80%; T2, 20% |
T1c, 68%; T2, 32% |
1, 8%; 2, 80%; 3, 12% |
1, 8%; 2, 88%; 3, 4% |
|||||||
| Hiba et al., 2014 | 99 | 100 | 61.8±5.1 | 62.5±6.31 | <30, 80%; ≥30, 20% |
<30, 74%; ≥30, 26% |
NA | NA | NA | NA | ≤6, 16%; =7, 75%; ≥8, 9% |
≤6, 41%; =7, 15%; ≥8, 8% |
T2, 66.3%; T3, 33.7% |
T2, 56.6%; T3, 43.4% |
NA | NA | |||||||
| Melinda et al., 2016 | 9 | 9 | 67 (61.0–68.5) | 67 (63.0–73.0) | 27.1 (25.3–32.2) | 29.2 (23.4–29.9) | 7.4 (5.9–11.2) | 6.7 (5.6–8.0) | 48 (44.0–59.1) | 70 (39.5–98.0) | NA | NA | NA | NA | NA | NA | |||||||
| Yaiesh et al., 2016 | 21 | 12 | The author stated no difference | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | ||||||||
| Nosov et al., 2016 | 42 | 44 | 61.8±6.9 | 62.9±7.1 | 26.9±3.02 | 27.4±3.2 | 13.0±9.7 | 12.9±7.6 | NA | NA | 6.7±0.68 | 6.7±3.2 | T2, 57.2%; T3–4, 42.8% |
T2, 68.2%; T3–4, 31.8% |
NA | NA | |||||||
| Sugi et al., 2017 | 75 | 123 | 68 [49–75] | 69 [45–76] | 24.3 (20.0–28.9) | 23.4 (17.7–30.0) | 7.1 (3.5–45.6) | 6.5 (2.0–42.5) | NA | NA | 7 [6–9] | 7 [6–9] | T1c, 56%; T2, 44% |
T1c, 70%; T2, 30% |
2 [1–3] | 2 [0–3] | |||||||
| Huang et al., 2018 | 36 | 37 | 62.1±6.9 | 63.5±7.4 | 23.1±2.1 | 23.5±2.2 | 13.33±8.01 | 15.40±10.59 | NA | NA | ≤6, 47%; =7, 36%; ≥8, 17% |
≤6, 43%; =7, 38%; ≥8, 19% |
T1, 44%; T2, 56% |
T1, 54%; T2, 46% |
1, 39%; 2, 42%; 3, 19% |
1, 43%; 2, 41%; 3, 16% |
|||||||
| Graham et al., 2019 | 63 | 63 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||||||
| Lin et al., 2019 | 124 | 164 | 70.9±3.6 | 70.0±4.3 | 20.3±1.5 | 20.4±1.4 | 44.5±22.3 | 36.8±23.2 | NA | NA | ≤6, 42%; =7, 29%; ≥8, 29% |
≤6, 46%; =7, 26%; ≥8, 28% |
T1–T2c, 32%; T3a, 35%; T3b–T4, 32% |
T1–T2c, 32%; T3a 29%; T3b–T4, 39% |
NA | NA | |||||||
E/F, ERAS/FTS; non-E/F, non- ERAS/FTS; BMI, body mass index; PSA, prostate-specific antigen; ASA, American Society of Anesthesiologists; ERAS, enhanced recovery after surgery; FTS, fast track surgery.